NCT01668433View on ClinicalTrials.gov

Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
G6PD NormalG6PD DeficientHealthy
Interventions
DRUG

Regimens (Primaquine, Methylene blue)

Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.

Trial Locations (1)

10400

Hospital for Tropical Diseases, Bangkok

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01668433 - Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency | Biotech Hunter | Biotech Hunter